The company confirmed it will host a webcast and conference call at 4:30 p.m. ET on the designated date to discuss the status of the program. This follows data released in late June, where Cumberland reported that additional analyses of cardiac biomarkers reinforced the cardioprotective potential observed during Phase 2 trials of the drug. The market remains focused on whether the upcoming session will provide concrete steps toward the next stage of development for the candidate.